Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | APP | P05067 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.32 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1136763 | 1.00 | RECQL (0.47) | RECQLMAPTLMNAAPPALDH1A1 | |
| SCHEMBL113525 | 1.00 | RECQL (0.47) | RECQLMAPTLMNAAPPALDH1A1 | |
| SCHEMBL30778633 | 0.87 | RECQL (0.39) | RECQLMAPTLMNAAPP | |
| SCHEMBL19723129 | 0.87 | GLO1 (0.48) | RECQLMAPTLMNAAPPALDH1A1 | |
| SCHEMBL3379220 | 0.79 | GLO1 (0.53) | MAPTLMNAALDH1A1EGLN1HPGD | |
| SCHEMBL13306415 | 0.79 | GLO1 (0.53) | MAPTLMNAALDH1A1EGLN1HPGD | |
| SCHEMBL1260639 | 0.78 | — | — | |
| SCHEMBL1260637 | 0.78 | — | — | |
| SCHEMBL18212657 | 0.76 | RECQL (0.47) | RECQLMAPTLMNAAPPALDH1A1 | |
| SCHEMBL14095057 | 0.73 | MAPT (0.50) | RECQLMAPTLMNAAPPALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11655248-B2 | Pyridone-pyrimidine derivative acting as KRAS G12C mutein inhibitor | MEDSHINE DISCOVERY INC. (CN) | 2023-05-23 | — | — | US | disclosed |
| US-8362043-B2 | Use in controlling apoptosis, as antiinflammatory agents, in treating autoimmune disease, as antiischemic agents, in treating cardiovascular disorders; for example, 3(R,S)-[2(S)-(3-Benzoylamino-2-oxo-2H-pyridin-1-yl)-3-phenyl-propionylamino]-5-fluoro-4-oxo-pentanoic acid | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-01-29 | — | — | US | disclosed |
| US-8362043-B2 | Use in controlling apoptosis, as antiinflammatory agents, in treating autoimmune disease, as antiischemic agents, in treating cardiovascular disorders; for example, 3(R,S)-[2(S)-(3-Benzoylamino-2-oxo-2H-pyridin-1-yl)-3-phenyl-propionylamino]-5-fluoro-4-oxo-pentanoic acid | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11655248-B2 | Pyridone-pyrimidine derivative acting as KRAS G12C mutein inhibitor | KRAS, NRAS, MSH2 | RECQL 112/4885MAPT 2882/4885LMNA 2671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.